Develops degradable hydrogel implants for orthopedic tissue repair, including GelrinC for knee cartilage injuries treated by orthopedic surgeons.
20-F for FY2025, filed Feb 24, 2026
No revenue reported yet.
20-F for FY2025, filed Feb 24, 2026
GelrinC is intended for orthopedic surgeons treating knee cartilage injuries. Regentis plans to market it in the United States through a strategic partner and to seek partners in Europe.
20-F for FY2025, filed Feb 24, 2026According to our knowledge, there is currently no approved off-the-shelf product in the United States for the cartilage repair market.…View ↗
If and when GelrinC is approved for commercial sale, we intend to market the product in the United States with a strategic partner. Our…View ↗
We have obtained a CE mark for marketing approval for GelrinC in Europe and plan to look for a strategic partner in connection therewith…View ↗
Competes with Vericel, Arthrex, ISTO Technologies, CartiHeal, and Smith & Nephew
20-F for FY2025, filed Feb 24, 2026MACI, an autologous cellular (patient’s own cells) treatment procedures available from Vericel Corp., or Vericel, which is the only…View ↗
Loading...
